研究概要
为更好地理解LGSC的生物学特性,我们对LGSC(n = 11)、HGSC(n = 19)和SBTs(n = 26)的福尔马林固定、石蜡包埋组织块进行了全蛋白质组分析。
中文摘要
低级别浆液性卵巢癌(LGSC)是一种罕见且致命的卵巢癌亚型。LGSC在病理学、生物学和临床上与更常见的高级别浆液性卵巢癌(HGSC)不同。LGSC起源于浆液性交界性卵巢肿瘤(SBT)。SBT向LGSC转化的机制仍知之甚少。为了更好地理解LGSC的生物学特性,我们对LGSC(n = 11)、HGSC(n = 19)和SBT(n = 26)的福尔马林固定、石蜡包埋组织块进行了全蛋白质组分析。我们发现全蛋白质组能够区分卵巢上皮性肿瘤的组织学类型。与肿瘤微环境相关的蛋白质在LGSC和SBT之间差异表达。成纤维细胞活化蛋白(FAP),一种在癌相关成纤维细胞中表达的蛋白质,是LGSC与SBT相比差异丰度最大的蛋白质。我们进行了免疫标志物(CD20、CD79a、CD3、CD8和CD68)的多重免疫组织化学(IHC)检测,以确定B细胞、T细胞和巨噬细胞的存在。LGSC的FAP+间质与更高丰度的Tregs和M2巨噬细胞相关,这些特征在SBT中不存在。我们的蛋白质组学队列揭示了LGSC与其推测的前驱病变SBT相比,肿瘤微环境存在变化。这些变化表明肿瘤微环境为LGSC的肿瘤发生和进展提供了支持性环境。因此,靶向LGSC的肿瘤微环境可能是一种可行的治疗策略。© 2024 The Pathological Society of Great Britain and Ireland.
展开英文摘要原文
Low-grade serous ovarian carcinoma (LGSC) is a rare and lethal subtype of ovarian cancer. LGSC is pathologically, biologically, and clinically distinct from the more common high-grade serous ovarian carcinoma (HGSC). LGSC arises from serous borderline ovarian tumours (SBTs). The mechanism of transformation for SBTs to LGSC remains poorly understood. To better understand the biology of LGSC, we performed whole proteome profiling of formalin-fixed, paraffin-embedded tissue blocks of LGSC (n = 11), HGSC (n = 19), and SBTs (n = 26). We identified that the whole proteome is able to distinguish between histotypes of the ovarian epithelial tumours. Proteins associated with the tumour microenvironment were differentially expressed between LGSC and SBTs. Fibroblast activation protein (FAP), a protein expressed in cancer-associated fibroblasts, is the most differentially abundant protein in LGSC compared with SBT. Multiplex immunohistochemistry (IHC) for immune markers (CD20, CD79a, CD3, CD8, and CD68) was performed to determine the presence of B cells, T cells, and macrophages. The LGSC FAP + stroma was associated with greater abundance of Tregs and M2 macrophages, features not present in SBTs. Our proteomics cohort reveals that there are changes in the tumour microenvironment in LGSC compared with its putative precursor lesion, SBT. These changes suggest that the tumour microenvironment provides a supportive environment for LGSC tumourigenesis and progression. Thus, targeting the tumour microenvironment of LGSC may be a viable therapeutic strategy. © 2024 The Pathological Society of Great Britain and Ireland.
论文信息
- 作者
- Vallejos R、Zhantuyakova A、Negri GL、Martin SD、Spencer SE、Thornton S、Leung S、Lynch B
- 第一作者单位
- Department of Genome Sciences and Technology, University of British Columbia, Vancouver, BC, Canada.Canada
- 通讯作者单位
- Department of Molecular Oncology, BC Cancer, Vancouver, BC, Canada.Canada
- 文献类型
- 非美国政府资助研究
- 期刊
- The Journal of pathology2024 Oct